---
title: HCC70 CDX Model - TD2 Precision Oncology
description: HCC70 is an instrumental cell line for studying the aggressive nature of triple-negative breast cancer, its unique molecular characteristics, and potential therapeutic interventions.
image: https://td2inc.com/hubfs/Assets/GraphsFigures/hcc70.png
---
×
[](https://td2inc.com/?hsLang=en)
[](https://td2inc.com/?hsLang=en)
# HCC70 CDX Model
The HCC70 cell line is derived from human triple-negative breast cancer (TNBC), one of the most aggressive subtypes of breast cancer that lacks expression of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2). HCC70 serves as a fundamental model for understanding the intricate biology of TNBC and for assessing potential therapeutic approaches. This cell line encapsulates many of the molecular features and genetic anomalies inherent to TNBC, underscoring its value for preclinical studies targeting this challenging breast cancer subtype. Through in vitro and in vivo experiments with HCC70, insights can be gleaned about TNBC’s aggressive growth patterns, metastatic tendencies, stromal interactions, and responsiveness to various therapeutic agents. Researchers rely on the HCC70 model to dissect the molecular underpinnings of TNBC and to develop and evaluate therapeutic strategies, especially those targeting the unique vulnerabilities of triple-negative tumors.
## Model Details
**Cancer Location:** Mammary Fat Pad
**Cancer Type:** Triple-Negative Breast Cancer
**Model Name:** HCC70
**Mouse Strain:** Nu/Nu
**Treatment Data Available:** Chemotherapy (Paclitaxel)
## HCC70 Growth curves
Growth of orthotopic (MFP) HCC70 in Nu/Nu mice (n=6)
### Request Additional CDX Model Data
## CONTACT US
## Get Started.
Have questions about how TD2 can assist with your regulatory needs? Reach out to our expert staff today to get started.
[Get Started Now](https://td2inc.com/contact-us/?hsLang=en)
[](https://td2inc.com/?hsLang=en)
Office
13208 E. Shea Blvd,
Suite 100
Scottsdale, AZ 85259
Phone
(602) 358-8300
Connect with us
-
-
© 2026 Translational Drug Development. All Rights Reserved. [Terms and Conditions](https://td2inc.com/terms-and-conditions?hsLang=en) | [Privacy Policy](https://td2inc.com/privacy-policy?hsLang=en)